Population Pharmacokinetic Analysis of Bisoprolol

SummaryThe technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential hypertension receiving multiple oral doses of bisoprolol 10 or 20mg for 3 months; group II, patients with different degrees of renal impairment and healthy controls; and group HI, patients with different types of hepatic impairment and healthy controls. Patients and controls in groups II and III received only a single oral dose of bisoprolol 10mg. The 3 data sets were analysed separately, using a non-linear mixed effects model (the NONMEM program). A 2-compartment pharmacokinetic model with first-order absorption described the data adequately. The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and O.7hr−1; for group II, 28L, 179L, and 0.3hr−l; and for group III, 55L, 256L, and 0.4hr−1, respectively. Plasma clearance was related to age in group I, to serum creatinine in group II and to aspartate transaminase activity in group HI. The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I. The analysis predicted that progressive increases in serum creatinine or aspartate transaminase activity will result in only a 50% reduction of clearance.

[1]  W. Ritschel Pharmacokinetic Approach to Drug Dosing in the Aged , 1976, Journal of the American Geriatrics Society.

[2]  G. Leopold Balanced Pharmacokinetics and Metabolism of Bisoprolol , 1985, Journal of cardiovascular pharmacology.

[3]  L B Sheiner,et al.  Premarketing observational studies of population pharmacokinetics of new drugs , 1985, Clinical pharmacology and therapeutics.

[4]  T. Grasela,et al.  An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies , 1986, Clinical pharmacology and therapeutics.

[5]  A. Kelman,et al.  Compilation of a clinical pharmacokinetic database for population analysis during drug development , 1987 .

[6]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[7]  E M Sorkin,et al.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. , 1988, Drugs.

[8]  K. Bühring,et al.  Basic Pharmacokinetics of Bisoprolol, a New Highly Beta1‐selective Adrenoceptor Antagonist , 1986, Journal of clinical pharmacology.

[9]  G. Leopold,et al.  Pharmacokinetics and Metabolism of Bisoprolol-14C in Three Animal Species and in Humans , 1985, Journal of cardiovascular pharmacology.

[10]  A W Kelman,et al.  Population Analysis of the Pharmacokinetic Variability of High-Dose Metoclopramide in Cancer Patients , 1988, Clinical pharmacokinetics.

[11]  A. Garbe,et al.  Determination of the new β-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography , 1986 .

[12]  W. Kirch,et al.  Pharmacokinetics of Bisoprolol During Repeated Oral Administration to Healthy Volunteers and Patients with Kidney or Liver Disease , 1987, Clinical pharmacokinetics.